Ro
Program terms need a fresh check
Edited by Designing Longevity Editorial · earlier profile checked May 1, 2026
Current program terms need a fresh check. Request a written care and medication quote. Earlier public-record dates are shown below.
Reviews of individual programs
Program reviews cover their own costs, terms and support. The program-terms checklist applies to the named care program, not every service offered by this company.
Ro GLP-1 program reviewProgram costs and payment terms
Current program terms need a fresh check. Get a written price and billing quote directly before paying.
- Membership
- Current membership price needs a fresh check.
- Insurance
- Insurance terms need a fresh check; confirm directly before paying.
Designing Longevity is a founder-led editorial publication. Our content is not medically reviewed.
The full profile and rubric were last checked May 1, 2026. Current commercial terms above have their own check date; they do not refresh earlier ratings or clinical claims.
Read the earlier full profile and source record (May 1, 2026)
This record keeps its original check dates. The program-terms checklist above covers costs, billing and advertised support for the named care program.
Earlier editorial take
Earlier review: best for
Patients who want one platform for multiple verticals
Ro covers weight loss, men's health, hair loss, fertility, and skincare. If you'd rather use one provider for several needs, Ro is the most credible multi-vertical option.
Users who value mature support infrastructure
Largest user base in the cohort and longest BBB tenure means the operation is well-rehearsed.
Our take
The full profile retains its earlier verification date. Check the dated program terms below before choosing.
Pros
- Both brand-name (Wegovy, Ozempic, Zepbound) and compounded options
- Established platform with mature support and largest user base in cohort
- BBB Accredited since 2018 (B rating)
- ConsumerAffairs review volume (21,800+) is the largest signal in our cohort and skews positive (4.4/5)
Cons
- April 2025 FDA finasteride alert reflects on Ro's compounder-vendor track record
- Compounded sourcing less transparent than vertically-integrated competitors
Pricing
Current pricing needs a fresh check.
Turnaround
Same-day Rx after async intake
States served
All 50
Earlier full review checked
May 1, 2026
Earlier rubric breakdown
How the earlier rating was scoredLicensure
20% weightLicense and enforcement records checked at the profile verification date.
Active multi-state licensure across 50 states; no FDA warning letter specifically on Ro at capture date. Counterweight: April 2025 FDA safety alert on compounded topical finasteride explicitly applies to compounders and telemedicine platforms, and Ro markets compounded topical finasteride, so the alert reflects on the company even though Ro wasn't named.
Evidence checked in the earlier review (4)
Roman Health Ventures, Inc. (operating entity)
Business filingLong-established corporate parent; founded 2017 as Roman, rebranded to Ro.
Checked May 1, 2026
No FDA warning letter on Ro / Roman Health Ventures
Federal databaseVerified against the FDA warning-letter database at capture date. None on record.
Checked May 1, 2026 · source
April 2025 FDA safety alert on compounded topical finasteride (industry-wide)
Federal alertFDA alert dated April 25, 2025 cites adverse events including suicidal ideation, depression, and erectile dysfunction tied to compounded topical finasteride. Ro markets compounded topical finasteride for hair loss, so the alert reflects on the company even though Ro is not named.
Checked May 1, 2026 · source
Active multi-state licensure
State licensureRo operates across all 50 states via licensed clinicians in each jurisdiction.
Checked May 1, 2026
Accreditation
20% weightAccreditation records checked at the profile verification date.
BBB Accredited since July 23, 2018 with a B rating, among the longest-tenured BBB-accredited telehealth platforms. LegitScript not independently confirmed on a public-registry URL at capture date (LegitScript doesn't publish a per-merchant directory); Ro advertises on Google and Meta, which generally requires LegitScript certification, so it's a strong inference.
Evidence checked in the earlier review (3)
BBB Accredited Business since July 23, 2018
AccreditationCurrent BBB rating: B. Long-tenured accreditation is itself a positive signal.
Checked May 1, 2026 · source
LegitScript Healthcare Merchant Certification
AccreditationInferred from Ro's active Google and Meta advertising (which requires LegitScript), but LegitScript does not publish a public per-merchant directory URL we could confirm against.
Checked May 1, 2026 · source
PCAB on partner compounding pharmacies
Partner accreditationRo uses partner compounding pharmacies for compounded GLP-1; specific partner accreditations not publicly disclosed at fill level.
Checked May 1, 2026
Transparency
20% weightPublished testing, sourcing, and formulation information.
Compounded sourcing details (which 503A or 503B partner) less granular than vertically-integrated competitors like Eden.
Evidence checked in the earlier review (2)
Compounded source pharmacy named per fill
SourcingRo uses a network of compounding partners; specific partner per fill is not surfaced publicly.
Checked May 1, 2026
"Compounded medications are not FDA-approved" disclosure published
Compliance disclosureChecked May 1, 2026
Product quality
15% weightPublished testing, recall, and supply-chain information.
This earlier product-quality score has not been refreshed. The commercial update does not recheck manufacturing, sourcing or clinical care.
Evidence checked in the earlier review (4)
No FDA recalls on Ro-distributed GLP-1 product
Recall historyChecked May 1, 2026 · source
Branded GLP-1 supply via authorized distribution
SourcingWegovy, Ozempic, and Zepbound dispensed through standard pharmaceutical supply chain.
Checked May 1, 2026
Compounded GLP-1 third-party lot testing program
TestingSpecific testing programs at partner pharmacies not publicly detailed at the per-fill level.
Checked May 1, 2026
Compounder-vendor management (cross-product line)
Vendor oversightApril 2025 FDA finasteride alert applies to compounders and telemedicine platforms; Ro's compounded topical finasteride line is in scope. Indicates a compounder-vendor track record that warrants scrutiny across product lines.
Checked May 1, 2026 · source
Pricing
15% weightValue within the category, no surprise fees, refund policy.
Current pricing needs a fresh check.
Customer service
10% weightRefund policy, support quality, complaint history.
Wide review-platform split: Trustpilot 3.7/5 across ~3,200, BBB B rating accredited since 2018, ConsumerAffairs 4.4/5 across ~21,800. The ConsumerAffairs volume is significant (far larger sample than Trustpilot) and skews more positive.
Evidence checked in the earlier review (3)
Trustpilot rating: 3.7/5 across 3,198 reviews
External reviewChecked May 1, 2026 · source
ConsumerAffairs rating: 4.4/5 across 21,848 reviews
External reviewLargest external review sample in our cohort; meaningfully more positive than Trustpilot.
Checked May 1, 2026 · source
Adverse-event reporting path documented
SafetyChecked May 1, 2026
Public reviews
What we found across third-party review platforms. These are external sentiment signals, not our scoring inputs.
Trustpilot
3.7 stars across 3,198 reviews, "Average" per Trustpilot's banding. Strongest themes: convenience, ease of use, professional support. Negatives concentrate on cancellation friction and surprise charges.
Better Business Bureau
BBB Accredited since July 23, 2018; current rating B. Telemedicine business in New York, NY. Complaint patterns: misleading headline pricing (membership vs medication), unexpected charges, refund difficulties on cancellation.
ConsumerAffairs
Markedly more positive than Trustpilot or BBB: 4.4/5 across 21,848 reviews. Largest review sample in our cohort by an order of magnitude. The split between platforms is wide enough to weigh both: ConsumerAffairs volume is meaningful, BBB pattern is also meaningful.
Regulatory & legal history
FDA enforcement actions, manufacturer lawsuits, recalls, and other notable events on the public record.
- FDA Warning LetterApril 25, 2025
FDA safety alert on compounded topical finasteride products cites 32 reports of adverse events between 2019-2024, including suicidal ideation, anxiety, depression, erectile dysfunction, and persistent symptoms after discontinuation. The alert applies to compounders and telemedicine platforms; Ro markets compounded topical finasteride for hair loss and is in scope even though not named in the alert.
Source
What to expect
- 1
Pharmacy fulfillment
3-7 daysApproved Rx routes to either an in-network pharmacy (branded) or a partner compounding pharmacy (compounded). Cold-chain shipping handled by the fulfilling pharmacy.
Accreditations
State pharmacy/clinic license
Verified · May 1, 2026
LegitScript Certified
Unverified · May 1, 2026 · source
Frequently asked
What does Ro charge for membership?
Current membership price needs a fresh check.
Does Ro accept insurance?
Insurance terms need a fresh check; confirm directly before paying.
Is Ro the same as Roman?
Yes. Ro was founded in 2017 as Roman, focused on men's health (ED, hair loss). The company rebranded to Ro and expanded into multiple verticals including weight loss (Ro Body), women's health, fertility, and dermatology. Operating entity is Roman Health Ventures, Inc., based in New York.
Is Ro BBB-accredited?
Yes. Ro has been BBB Accredited since July 23, 2018 with a current rating of B. The profile is at https://www.bbb.org/us/ny/new-york/profile/telemedicine/ro-0121-173581 if you want to read complaints directly. Long-tenured BBB accreditation is itself a positive signal.
Why is Ro flagged for the FDA finasteride alert?
On April 25, 2025, the FDA issued a safety alert about compounded topical finasteride products, citing 32 reports of adverse events including suicidal ideation, anxiety, and persistent symptoms after discontinuation. The alert explicitly applies to compounders and telemedicine platforms. The FDA didn't name Ro specifically, but Ro markets compounded topical finasteride for hair loss, so the alert reflects on the company's compounder-vendor management even though it's a different product line from GLP-1.
Update history
Every meaningful change to this profile, with a date stamp. We don't silently re-score.
- May 1, 2026
Initial published profile. Sources HEAD-checked at publish time. Score reflects honest math after surfacing the April 2025 FDA finasteride alert (industry-wide but applies to Ro's product mix), the BBB complaint pattern around membership-vs-medication billing transparency, and the wide review-platform split (Trustpilot 3.7 vs ConsumerAffairs 4.4 vs BBB B). Insurance concierge for branded GLP-1 remains the genuine differentiator.
Compare Ro head-to-head
Compare dated terms, public records and the questions still needing verification.
vs Mochi Health
Compare Mochi Health and Ro using dated program terms and clearly labeled evidence limits.
Read comparisonvs Eden
Compare Ro and Eden using dated program terms and clearly labeled evidence limits.
Read comparisonvs Henry Meds
Compare Ro and Henry Meds using dated program terms and clearly labeled evidence limits.
Read comparisonvs Hims & Hers
Compare Ro and Hims weight-loss care fees, insurance help and subscription terms using dated sources. Check medication costs and eligibility.
Read comparisonvs TrimRx
Compare TrimRx and Ro using dated program terms and clearly labeled evidence limits.
Read comparisonEdited by Designing Longevity Editorial. Earlier profile checked May 1, 2026.
Spot something out of date or wrong? Let us know and we'll re-check.
Back to all providers